April 2026
1. SATO Y, Fujii Y, Kume H
   Cancer Genomic Medicine for Urological Malignancies in Japan.
   Int J Urol. 2026;33:e70449.
   

   >> Share

   
   
2. TAKAHASHI S
   Editorial Comment to Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low- and Intermediate-Risk Localized Prostate Cancer.
   Int J Urol. 2026;33:e70457.
   

   >> Share

   
   
3. HONDA K, Oka S, Makiyama K, Tatenuma T, et al
   Artificial Intelligence-Based Recognition of the Prostatic Capsule During Nerve-Sparing Robot-Assisted Radical Prostatectomy.
   Int J Urol. 2026;33:e70454.
   

   >> Share

   
   March 2026
4. IIDA K, Hayashi Y, Narita K, Itami Y, et al
   Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low- and Intermediate-Risk Localized Prostate Cancer.
   Int J Urol. 2026;33:e70391.
   

   >> Share

   
   
5. KOYAMA Y, Morizane S, Moriyasu E, Hoshino T, et al
   Effect of Neoadjuvant Chemo-Hormonal Therapy on Reducing Recurrence in Patients With Very High-Risk Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy.
   Int J Urol. 2026;33:e70387.
   

   >> Share

   
   
6. UCHIDA K, Watanabe H, Matsushita Y, Tamura K, et al
   Robot-Assisted Radical Cystectomy Using the Hinotori Surgical System in Patients With Previous Prostate Cancer Treatment: A Single-Institution Case Series.
   Int J Urol. 2026;33:e70383.
   

   >> Share

   
   
7. HIBINO T, Kato M, Tsuzuki T, Nishikimi T, et al
   Total Positive Margin Length as a Novel Prognostic Indicator After Radical Prostatectomy.
   Int J Urol. 2026;33:e70395.
   

   >> Share

   
   
8. SUGINO A, Miyazawa Y, Nakazawa S, Tsuji Y, et al
   Active Surveillance for Localized Prostate Cancer: A Retrospective Single-Center Study.
   Int J Urol. 2026;33:e70433.
   

   >> Share

   
   
9. YAEGASHI H, Nakashima K, Miwa S, Miyagi T, et al
   Clinical Validation of the Prostate Health Index for Detecting Clinically Significant Prostate Cancer in a Population-Based Screening Program.
   Int J Urol. 2026;33:e70409.
   

   >> Share

   
   
10. IWAMOTO H, Hori T, Inaba T, Nakagawa R, et al
    Prognostic Significance of Radiographic Progression at Metastatic Castration-Resistant Prostate Cancer Diagnosis.
    Int J Urol. 2026;33:e70435.
    

    >> Share

    
    
11. KAZASHI K, Washino S, Saito K, Oshiro H, et al
    Functional and Oncological Outcomes of Novel Anterior, Retzius-Sparing, and Conventional Anterior Approaches in Robot-Assisted Radical Prostatectomy: A Comparative Cohort Study.
    Int J Urol. 2026;33:e70412.
    

    >> Share

    
    February 2026
12. HATAKEYAMA S, Yoneyama T, Ohyama C
    Beyond Total PSA: Clinical Significance of S2,3PSA% in Reducing Unnecessary Prostate Biopsies.
    Int J Urol. 2026;33:e70371.
    

    >> Share

    
    
13. SASAKI T, Igarashi A, Ebara S, Tatenuma T, et al
    Prognostic Factors of Castration-Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot-Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort (MSUG94).
    Int J Urol. 2026;33:e70370.
    

    >> Share

    
    
14. MIURA N, Shimbo M, Shishido K, Nobumori S, et al
    Impact of the 2025 NCCN Definition Change for Very High-Risk Prostate Cancer on Surgical Outcomes After Robot-Assisted Radical Prostatectomy: A Retrospective Cohort.
    Int J Urol. 2026;33:e70366.
    

    >> Share

    
    
15. UMEMORI M, Urabe F, Iwamoto Y, Imai Y, et al
    Impact of Immunohistochemical PSA and Ki-67 Expression on Prognosis in Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2026;33:e70368.
    

    >> Share

    
    
16. TAKAHARA K, Takeuchi A, Saruta M, Yoshizawa A, et al
    Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: Current Evidence and Future Directions.
    Int J Urol. 2026;33:e70375.
    

    >> Share

    
    
17. DAGLI I, Canbolat MZ, Uzel T, Cayirli A, et al
    Local Anesthetic Transperineal Prostate Biopsy: Does It Affect Uroflowmetry Results.
    Int J Urol. 2026;33:e70377.
    

    >> Share

    
    
18. CHEN W, Yoshida S, Yajima S, Tanabe K, et al
    Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Time-Dependent Analysis of Reconstructed Individual Patient Data From the PEACE-3 Trial.
    Int J Urol. 2026;33:e70376.
    

    >> Share

    
    
19. KOBAYASHI S, Shiota M, Onozawa M, Taguchi S, et al
    To Investigate Disparities in Strategies for Low-Risk Prostate Cancer by Facility Type Using the Japan Study Group of Prostate Cancer Database.
    Int J Urol. 2026;33:e70381.
    

    >> Share

    
    
20. TANABE K, Yoshida S, Chen W, Yajima S, et al
    Bayesian Multi-Criteria Decision Analysis of Net Clinical Benefit in ARASENS: Overall and Japanese Subgroup Results.
    Int J Urol. 2026;33:e70384.
    

    >> Share

    
    
21. TAKAHASHI H, Fukuokaya W, Muramoto K, Katsumi K, et al
    Real-World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Int J Urol. 2026;33:e70369.
    

    >> Share

    
    January 2026
22. TAMADA T, Takeuchi M, Moriya K, Ueda Y, et al
    The Evolution of Prostate Multiparametric MRI and Its Application in Prostate Cancer Clinical Management.
    Int J Urol. 2026 Jan 7. doi: 10.1111/iju.70338.
    

    >> Share

    
    
23. ALKAN VURGUN N, Sen Turk N, Vurgun S, Yagci AB, et al
    Risk-Stratified Gleason Upgrading in ISUP Grade Group 1 Prostate Cancer: Combined Analysis of TMPRSS2-ERG, PTEN, Ki-67, and MRI-Derived Apparent Diffusion Coefficient Values.
    Int J Urol. 2026;33:e70346.
    

    >> Share

    
    
24. MASUDA N, Hazama T, Hosomi T, Imai K, et al
    Technique Selection for Robot-Assisted Radical Prostatectomy: A Multi-Institutional Survey in Japan.
    Int J Urol. 2026;33:e70347.
    

    >> Share

    
    
25. UENO Y
    Editorial Comment on "The Evolution of Prostate Multiparametric MRI and Its Application in Prostate Cancer Clinical Management".
    Int J Urol. 2026;33:e70353.
    

    >> Share

    
    
26. KAR F
    Editorial Comment on (Abiraterone Acetate Triggers ER Stress-Mediated Androgen Receptor Suppression via PERK/ATF4/CHOP Signaling in Prostate Cancer).
    Int J Urol. 2026;33:e70352.
    

    >> Share

    
    
27. MASSOUH K, Leucht K, Leistritz L, Grimm MO, et al
    Retrospective Analysis of Vesicourethral-Anastomosis Stricture/Urethral Stricture After Robotic-Assisted Laparoscopic Radical Prostatectomy With and Without Radiotherapy.
    Int J Urol. 2026;33:e70339.
    

    >> Share

    
    
28. SUZUKI Y, Sonobe S, Kawasaki Y, Ikumi S, et al
    Operative Time Prediction by Machine Learning for Robot-Assisted Laparoscopic Radical Prostatectomy.
    Int J Urol. 2026;33:e70292.
    

    >> Share

    
    
29. TANAKA H, Kobayashi M, Matsumoto S, Ishikawa Y, et al
    Impact of Approach Routes in MRI-Ultrasound Fusion Prostate Biopsy on Post-Biopsy Complications: A Propensity Score-Matched Analysis.
    Int J Urol. 2026;33:e70275.
    

    >> Share

    
    
30. MAKABE S, Hata J, Tsumori T, Hiraguri A, et al
    Abdominal Subcutaneous Fat Thickness Is a Useful Predictor for Lower Urinary Tract Dysfunction After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70249.
    

    >> Share

    
    
31. ISHII N, Yoneyama T, Minakawa S, Konishi S, et al
    Immediate Postoperative cfDNA Elevation Predicts Pain After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70297.
    

    >> Share

    
    
32. MONCADA I, Krishnappa P, Fraile-Poblador A, Moscatiello P, et al
    A Comparative Study of Simultaneous and Delayed Penile Prosthesis During Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70285.
    

    >> Share

    
    December 2025
33. FUKIAGE Y, Taga M, Inamura M, Kaeriyama K, et al
    Magnetic Resonance Imaging-Transrectal Ultrasound Fusion-Targeted Biopsy Improves the Diagnostic Efficacy of Overall and Clinically Significant Prostate Cancer.
    Int J Urol. 2025 Dec 26. doi: 10.1111/iju.70334.
    

    >> Share

    
    
34. HAGIMOTO H, Sakamoto S, Sato K, Nakamura K, et al
    Impact of Age on Treatment Patterns and Outcomes in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70326.
    

    >> Share

    
    
35. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
    Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
    

    >> Share

    
    
36. KOKETSU Y, Iwamoto H, Hiratsuka K, Inaba T, et al
    Whole-Blood RNA Expression of Immunosuppressive Cell-Related Genes Is Associated With Prostate Cancer Progression.
    Int J Urol. 2025 Dec 21. doi: 10.1111/iju.70323.
    

    >> Share

    
    
37. WATANABE R
    DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade.
    Int J Urol. 2025 Dec 10. doi: 10.1111/iju.70317.
    

    >> Share

    
    
38. URABE F
    Editorial Comment on "DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade".
    Int J Urol. 2025 Dec 8. doi: 10.1111/iju.70311.
    

    >> Share

    
    
39. BASARAN E, Hacioglu C
    Abiraterone Acetate Triggers ER Stress-Mediated Androgen Receptor Suppression via PERK/ATF4/CHOP Signaling in Prostate Cancer.
    Int J Urol. 2025 Dec 3. doi: 10.1111/iju.70304.
    

    >> Share

    
    
40. MITSUNARI K, Nakamura Y, Imamura R
    Editorial Comments on the Preliminary Analysis of Prostate Cancer Screening Results and Exploration of a Screening Model for Elderly Males in Rural Areas of Songjiang District, Shanghai.
    Int J Urol. 2025 Dec 3. doi: 10.1111/iju.70308.
    

    >> Share

    
    
41. OKAMOTO K, Ozawa Y, Kayaba T, Koike S, et al
    Does Accessory Pudendal Artery Preservation Increase the Risk of Positive Surgical Margins in Robot-Assisted Radical Prostatectomy?
    Int J Urol. 2025;32:1762-1770.
    

    >> Share

    
    November 2025
42. SAKO S, Ito S, Ueda T, Gabata Y, et al
    DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade.
    Int J Urol. 2025 Nov 27. doi: 10.1111/iju.70299.
    

    >> Share

    
    
43. FANG D, Bi S, Wu L, Wang C, et al
    Preliminary Analysis of Prostate Cancer Screening Results and Exploration of Screening Model for Elderly Males in Rural Areas of Songjiang District, Shanghai.
    Int J Urol. 2025 Nov 21. doi: 10.1111/iju.70274.
    

    >> Share

    
    
44. HASHIZUME A
    Editorial Comment on Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Nov 17. doi: 10.1111/iju.70262.
    

    >> Share

    
    
45. KANEKO G
    Editorial Comment to "Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A Preliminary Prospective Study".
    Int J Urol. 2025 Nov 4. doi: 10.1111/iju.70278.
    

    >> Share

    
    
46. NISHINO T, Shimbo M, Sano M, Oguchi T, et al
    Incidence, Risk Factors, and Clinical Characteristics of Late Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:1688-1695.
    

    >> Share

    
    
47. KOHADA Y, Kitano H, Tasaka S, Ono Y, et al
    Association Between Preoperative Penile Circumference and Urinary Function After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:1576-1586.
    

    >> Share

    
    
48. NAKAMURA M, Muraki Y, Yamada Y, Matsumoto S, et al
    Impact of Enhanced Recovery After Surgery Protocol on Perioperative Quality of Life in Robot-Assisted Radical Prostatectomy: A Single-Center Prospective Cohort Study.
    Int J Urol. 2025;32:1561-1568.
    

    >> Share

    
    October 2025
49. AIZAWA R, Mizowaki T
    Editorial Comment on "Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer".
    Int J Urol. 2025 Oct 29. doi: 10.1111/iju.70272.
    

    >> Share

    
    
50. URABE F
    Editorial Comment on Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial.
    Int J Urol. 2025 Oct 26. doi: 10.1111/iju.70269.
    

    >> Share

    
    
51. KAWAHARA T
    Re: Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70259.
    

    >> Share

    
    
52. ALANBUKI A
    Editorial Comment: Prostate-Specific Antigen Dynamics and Bone Predominance as Predictors of Efficacy in Radium-223 Treatment for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70264.
    

    >> Share

    
    
53. YAJIMA S, Yoshida S, Fukushima H, Hirakawa A, et al
    Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial.
    Int J Urol. 2025 Oct 12. doi: 10.1111/iju.70256.
    

    >> Share

    
    
54. SUZUKI K, Khan N, Taguchi T, Hattori K, et al
    Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Oct 3. doi: 10.1111/iju.70235.
    

    >> Share

    
    
55. SASAKI T, Higashi S, Nishikawa T, Sugino Y, et al
    Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A Preliminary Prospective Study.
    Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70251.
    

    >> Share

    
    
56. YASUDA Y, Yoshida S, Matsubara D, Takahara T, et al
    Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70253.
    

    >> Share

    
    
57. ESCANDE R, Jaouen T, Gonindard-Melodelima C, Crouzet S, et al
    External Validation on a Japanese Cohort of a Computer-Aided Diagnosis System Aimed at Characterizing ISUP >/= 2 Prostate Cancers at Multiparametric MRI.
    Int J Urol. 2025;32:1440-1448.
    

    >> Share

    
    September 2025
58. DENIZ ME, Gur G, Kayra MV, Hasbay B, et al
    PSMA PET/CT and Multiparametric MRI in Assessing Local Extension and Lymph Node Metastasis in Prostate Cancer.
    Int J Urol. 2025 Sep 24. doi: 10.1111/iju.70239.
    

    >> Share

    
    
59. MIYOSHI Y, Uemura H, Ohta J, Kobayashi K, et al
    Prognostic Value of BONENAVI Computer-Aided Diagnosis System Bone Scans as an Imaging Biomarker for Bone-Metastatic Castration-Sensitive Prostate Cancer: An Investigator-Initiated, Multicenter, Prospective Observational Study.
    Int J Urol. 2025 Sep 23. doi: 10.1111/iju.70214.
    

    >> Share

    
    
60. HATANO K
    Editorial Comment on "Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis".
    Int J Urol. 2025 Sep 17. doi: 10.1111/iju.70236.
    

    >> Share

    
    
61. NAKAJIMA Y, Hashimoto K, Shindo T, Kobayashi K, et al
    Prostate-Specific Antigen Dynamics and Bone Predominance as Predictors of Efficacy in Radium-223 Treatment for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Sep 16. doi: 10.1111/iju.70229.
    

    >> Share

    
    
62. SUZUKI K, Hirata J, Ueki H, Wakita N, et al
    Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis.
    Int J Urol. 2025 Sep 3. doi: 10.1111/iju.70219.
    

    >> Share

    
    
63. MATSUYAMA N, Suzuki K, Tobe T, Ueki H, et al
    Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Sep 2. doi: 10.1111/iju.70217.
    

    >> Share

    
    
64. KAWASE M
    Editorial Comment Regarding "Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection".
    Int J Urol. 2025 Sep 1. doi: 10.1111/iju.70218.
    

    >> Share

    
    August 2025
65. ARAI S
    Editorial Comment on Efficacy of Docetaxel Addition to Next-Generation Androgen Receptor-Axis-Targeted Therapies and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Tumor Volume-Specific Analysis.
    Int J Urol. 2025 Aug 21. doi: 10.1111/iju.70208.
    

    >> Share

    
    
66. IWAMOTO H, Hori T, Inaba T, Nakagawa R, et al
    Prognostic Impact of Time to Castration Resistance on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70197.
    

    >> Share

    
    
67. SHIMOMURA T
    Editorial Comment to "Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study".
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70185.
    

    >> Share

    
    
68. YAMAMOTO Y, Fujimoto S, Hashimoto M, Minami T, et al
    Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70202.
    

    >> Share

    
    
69. YASUDA Y, Wang Z, Yoshida S, Chen W, et al
    Indirect Comparison of PROpel and TALAPRO-2 Trials Using the Shiny Method: A Comparative Analysis in Metastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Aug 12. doi: 10.1111/iju.70194.
    

    >> Share

    
    
70. ARAI S
    Editorial Comment on Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
    Int J Urol. 2025 Aug 10. doi: 10.1111/iju.70201.
    

    >> Share

    
    
71. TOHI Y, Kato T, Fujiwara K, Harada S, et al
    Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection.
    Int J Urol. 2025 Aug 3. doi: 10.1111/iju.70193.
    

    >> Share

    
    
72. SOMOTO T, Utsumi T, Ishitsuka N, Noro T, et al
    Clinical Predictors of Fluoroquinolone-Resistant Escherichia coli in Transrectal Ultrasound-Guided Prostate Biopsy: Insights for Tailored Prophylaxis.
    Int J Urol. 2025;32:982-989.
    

    >> Share

    
    July 2025
73. HIRATA H
    Editorial Comment on "Frontiers of Ultrasound Technology in Prostate Cancer Treatment".
    Int J Urol. 2025 Jul 19. doi: 10.1111/iju.70183.
    

    >> Share

    
    
74. MITSUI Y, Nakajima K
    Editorial Comment on "Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy".
    Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70166.
    

    >> Share

    
    June 2025
75. SHOJI S, Takahashi K, Naruse J, Kawamura Y, et al
    Frontiers of Ultrasound Technology in Prostate Cancer Treatment.
    Int J Urol. 2025 Jun 22. doi: 10.1111/iju.70160.
    

    >> Share

    
    
76. TASHIRO K, Mori K, Shiota M, Fukuokaya W, et al
    Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70149.
    

    >> Share

    
    
77. YASUDA Y, Numao N, Matsumoto S, Tamiya T, et al
    Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70154.
    

    >> Share

    
    
78. WATANABE R
    Editorial Comment to "VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m6A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species".
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70150.
    

    >> Share

    
    
79. OKUDA Y, Kato T, Ishizuya Y, Hayashi T, et al
    PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer.
    Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70100.
    

    >> Share

    
    
80. PATTOU M, Neuzillet Y, Ghoneim T, Bosset PO, et al
    Evaluating the Safety of Delaying Surgery Beyond 9 Months in Localized Prostate Cancer Patients: Results From a Prospective Study With Propensity Score Matching.
    Int J Urol. 2025 Jun 4. doi: 10.1111/iju.70142.
    

    >> Share

    
    
81. MA J, Qu X
    VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m(6)A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species.
    Int J Urol. 2025 Jun 3. doi: 10.1111/iju.70140.
    

    >> Share

    
    
82. FALKENBACH F, Penaranda NR, Longoni M, Marmiroli A, et al
    The Effect of Chronic Kidney Disease on Adverse In-Hospital Outcomes at Radical Prostatectomy.
    Int J Urol. 2025;32:710-717.
    

    >> Share

    
    
83. KIMURA Y, Honda M, Yamane H, Shimizu R, et al
    Outcomes in Health-Related Quality of Life and Impact of Urinary Incontinence on Health-Related Quality of Life 7 Years After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:664-671.
    

    >> Share

    
    May 2025
84. ZHAO X, Sakamoto S, Yamada Y, Sato K, et al
    The Role of Serum Testosterone in the Pathogenesis and Treatment of Prostate Cancer: A Review Based on the Clinical Evidence.
    Int J Urol. 2025 May 23. doi: 10.1111/iju.70125.
    

    >> Share

    
    
85. REIKE MJ, Tully KH, Schulmeier M, Reicherz A, et al
    Functional Outcomes in Patients With Prostate Cancer Undergoing Frozen Section Guided Radical Prostatectomy.
    Int J Urol. 2025 May 20. doi: 10.1111/iju.70115.
    

    >> Share

    
    
86. HATANO K
    Editorial Comment on "Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?".
    Int J Urol. 2025 May 7. doi: 10.1111/iju.70093.
    

    >> Share

    
    April 2025
87. ROLDAN-TESTILLANO R, Sanchez-Salas R
    Editorial Comment on "Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study".
    Int J Urol. 2025 Apr 25. doi: 10.1111/iju.70083.
    

    >> Share

    
    
88. NORO T, Utsumi T, Ishitsuka N, Suzuki Y, et al
    Impact of the COVID-19 Pandemic on Prostate Cancer: Perturbations in Screening and Diagnostic Patterns.
    Int J Urol. 2025 Apr 24. doi: 10.1111/iju.70085.
    

    >> Share

    
    
89. CHEN W, Yoshida S, Fujii Y
    Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?
    Int J Urol. 2025 Apr 17. doi: 10.1111/iju.70072.
    

    >> Share

    
    
90. BLAS L, Shiota M, Kato T, Matsumoto R, et al
    Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study.
    Int J Urol. 2025 Apr 7. doi: 10.1111/iju.70063.
    

    >> Share

    
    
91. DLAMINI KCS, Coetzee LJ, Mathabe K
    South African single surgeon experience: Comparison of oncological outcomes, robot-assisted radical prostatectomy versus open perineal radical prostatectomy.
    Int J Urol. 2025;32:423-426.
    

    >> Share

    
    
92. FUNAJIMA K, Naito S, Fukai A, Narisawa T, et al
    Urinary continence outcomes after robot-assisted laparoscopic radical prostatectomy: Significance of anterior reconstruction.
    Int J Urol. 2025;32:355-360.
    

    >> Share

    
    
93. KAWAMURA N, Nakayama M, Hayashi T, Nagahara A, et al
    Risk assessment of late biochemical recurrence after radical prostatectomy: Usefulness of ultra-sensitive prostate-specific antigen measurement.
    Int J Urol. 2025;32:380-386.
    

    >> Share

    
    March 2025
94. YAMAMOTO Y
    Editorial Comments to "Overuse of Imaging in Prostate Cancer Staging".
    Int J Urol. 2025 Mar 24. doi: 10.1111/iju.70021.
    

    >> Share

    
    
95. SEKINE Y, Fujizuka Y, Nakazawa S, Tsuji Y, et al
    Utility of Combining Prostate Health Index and Magnetic Resonance Imaging for the Diagnosis of Prostate Cancer.
    Int J Urol. 2025 Mar 17. doi: 10.1111/iju.70024.
    

    >> Share

    
    
96. ONISHI K, Nakai Y, Tachibana A, Nishimura N, et al
    Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose-Rate Brachytherapy for Prostate Cancer.
    Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70018.
    

    >> Share

    
    
97. SEKITO T, Sadahira T
    Editorial Comment on Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose Rate Brachytherapy for Prostate Cancer.
    Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70035.
    

    >> Share

    
    
98. GUNGE N, Fukuhara Y, Matsuoka W, Fumihiro Y, et al
    Effect of ICG fluorescence-assisted new nerve-sparing of robot-assisted radical prostatectomy on lower urinary tract symptoms.
    Int J Urol. 2025;32:285-292.
    

    >> Share

    
    
99. MITSUI M, Sadahira T, Nagasaki N, Maruyama Y, et al
    Postoperative infections after robotic-assisted radical prostatectomy in a single large institution: Effect of type and duration of prophylactic antibiotic administration.
    Int J Urol. 2025;32:258-263.
    

    >> Share

    
    February 2025
100. MATSUOKA Y
     Editorial Comment to "Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer".
     Int J Urol. 2025 Feb 27. doi: 10.1111/iju.70031.
     

     >> Share

     
     
101. SUZUKI K, Matsuyama H, Matsubara N, Kazama H, et al
     Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.
     Int J Urol. 2025 Feb 25. doi: 10.1111/iju.70019.
     

     >> Share

     
     
102. URABE F, Kimura S
     Considerations on the Optimal Imaging for Prostate Cancer Diagnosis.
     Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70016.
     

     >> Share

     
     
103. HSIEH PF, Naruse J, Yuzuriha S, Umemoto T, et al
     Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer.
     Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70013.
     

     >> Share

     
     
104. IWAMOTO H, Izumi K, Mizokami A
     Editorial Comment on the Overuse of Imaging in Prostate Cancer Staging.
     Int J Urol. 2025 Feb 17. doi: 10.1111/iju.70015.
     

     >> Share

     
     
105. TOHI Y, Kato T, Kohashiguchi K, Kaji A, et al
     Overuse of imaging in prostate cancer staging.
     Int J Urol. 2025 Feb 3. doi: 10.1111/iju.70003.
     

     >> Share

     
     
106. HIROSE K, Nakanishi Y, Ogasawara RA, Imasato N, et al
     Risk factors for rectal wall infiltration in hydrogel spacer placement: Influence of biopsy approach.
     Int J Urol. 2025;32:183-189.
     

     >> Share

     
     
107. MINAMI T, Fujimoto S, Fujita K
     Iodine-125 low-dose rate prostate brachytherapy.
     Int J Urol. 2025;32:130-137.
     

     >> Share

     
     January 2025
108. ARAI S
     Editorial Comment on "Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study".
     Int J Urol. 2025 Jan 21. doi: 10.1111/iju.15682.
     

     >> Share

     
     
109. WASHINO S, Saito K, Yazaki K, Miyagawa T, et al
     A novel anterior approach toward robotic radical prostatectomy is associated with earlier continence recovery than the conventional approach.
     Int J Urol. 2025;32:80-87.
     

     >> Share

     
     
110. KOBAYASHI K, Nofuji S, Okabe K, Yorozuya W, et al
     How do Japanese patients really feel about losing potency after radical prostatectomy? (MAJI study).
     Int J Urol. 2025;32:69-72.
     

     >> Share

     
     
111. TEISHIMA J, Wakita N, Bando Y, Okamura Y, et al
     Effects of modifying hinotori surgical robot system on perioperative outcome of robot-assisted radical prostatectomy.
     Int J Urol. 2025;32:45-50.
     

     >> Share

     
     December 2024
112. CHEN W, Yoshida S, Miura N, Fukuda S, et al
     Efficacy of docetaxel addition to next-generation androgen receptor-axis-targeted therapies and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A tumor volume-specific analysis.
     Int J Urol. 2024 Dec 20. doi: 10.1111/iju.15657.
     

     >> Share

     
     
113. KUMAR V, Jena D, Zahiruddin QS, Roopashree R, et al
     Prostate cancer burden in South Asia: A systematic analysis of global burden of disease data (1990-2021).
     Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15641.
     

     >> Share

     
     
114. SUZUKI H, Akamatsu S, Shiota M, Kakiuchi H, et al
     Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.
     Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15647.
     

     >> Share

     
     
115. YE DW, Uemura H, Chung BH, Suzuki H, et al
     Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.
     Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15615.
     

     >> Share

     
     
116. MORIZANE S, Miki J, Shimbo M, Kanno T, et al
     Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
     Int J Urol. 2024;31:1300-1310.
     

     >> Share

     
     November 2024
117. HAKOZAKI Y, Yamada Y, Fujimura T, Kimura N, et al
     Novel clipping procedure for preventing post-operative inguinal hernia in robot-assisted radical prostatectomy.
     Int J Urol. 2024;31:1241-1247.
     

     >> Share

     
     October 2024
118. OBINATA D, Yamada Y, Sumiyoshi T, Tanegashima T, et al
     Recent advances in basic research on prostate cancer: Where we are heading?
     Int J Urol. 2024 Oct 30. doi: 10.1111/iju.15628.
     

     >> Share

     
     
119. SHIOTA M
     Editorial Comment to Loss of phosphatase and tensin homolog expression in castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
     Int J Urol. 2024 Oct 15. doi: 10.1111/iju.15607.
     

     >> Share

     
     
120. SATO M, Osawa T, Nishioka K, Miyazaki T, et al
     Decision regret after curative treatment and its association with the decision-making process and quality of life for prostate cancer patients.
     Int J Urol. 2024 Oct 9. doi: 10.1111/iju.15602.
     

     >> Share

     
     
121. YANAI Y, Mikami S, Yasumizu Y, Takeda T, et al
     Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
     Int J Urol. 2024 Oct 1. doi: 10.1111/iju.15592.
     

     >> Share

     
     
122. KOHADA Y, Kitano H, Tasaka R, Miyamoto S, et al
     Clinical characteristics and predictors of long-term postoperative urinary incontinence in patients treated with robot-assisted radical prostatectomy: A propensity-matched analysis.
     Int J Urol. 2024;31:1145-1152.
     

     >> Share

     
     September 2024
123. MITSUI Y, Nakajima K
     Editorial Comment to "Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis".
     Int J Urol. 2024 Sep 26. doi: 10.1111/iju.15582.
     

     >> Share

     
     
124. GUO X, Zhang F, Hao G
     Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis.
     Int J Urol. 2024 Sep 22. doi: 10.1111/iju.15565.
     

     >> Share

     
     
125. SHIMADA K, Fujiwara M, Hirahara D, Takaya E, et al
     Monitoring prostate cancer after low-dose-rate hemigland brachytherapy with delta-radiomics of diffusion-weighted magnetic resonance imaging.
     Int J Urol. 2024 Sep 11. doi: 10.1111/iju.15581.
     

     >> Share

     
     
126. KAMBE T, Yamasaki T, Yamamoto A, Nagoshi A, et al
     Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
     Int J Urol. 2024 Sep 10. doi: 10.1111/iju.15579.
     

     >> Share

     
     
127. KATO T, Tohi Y, Okazoe H, Taoka R, et al
     How widespread is active surveillance of early-stage prostate cancer in Japan? Multicenter questionnaire survey on the status of active surveillance of early-stage prostate cancer in Japan.
     Int J Urol. 2024 Sep 4. doi: 10.1111/iju.15573.
     

     >> Share

     
     
128. MORITA M, Hiramatsu A, Nishimura K, Yanagida W, et al
     Radiation proctitis after iodine-125 low-dose-rate prostate brachytherapy utilizing SpaceOAR hydrogel.
     Int J Urol. 2024;31:1001-1008.
     

     >> Share

     
     
129. COLAKOGLU Y, Eksi M, Ozlu DN, Simsek A, et al
     Comparison of oncological and functional results of robotic and open perineal radical prostatectomy.
     Int J Urol. 2024;31:994-1000.
     

     >> Share

     
     August 2024
130. MATSUOKA Y
     Editorial Comment to "Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?".
     Int J Urol. 2024 Aug 24. doi: 10.1111/iju.15566.
     

     >> Share

     
     
131. MIURA H, Hatakeyama S, Tabata R, Fujimori D, et al
     Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.
     Int J Urol. 2024 Aug 23. doi: 10.1111/iju.15550.
     

     >> Share

     
     
132. MADENDERE S, Kilic M, Gurses B, Vural M, et al
     Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?
     Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15553.
     

     >> Share

     
     
133. GOTO Y
     Editorial Comment on Japanese clinical practice guidelines for prostate cancer 2023.
     Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15562.
     

     >> Share

     
     
134. URABE F, Kimura S, Tashiro K
     Is meta-analysis effective in evaluating local treatment benefits for oligometastatic prostate cancer?
     Int J Urol. 2024 Aug 1. doi: 10.1111/iju.15555.
     

     >> Share

     
     
135. TOHI Y, Osaki Y, Kato T, Honda T, et al
     Impact of the coronavirus disease pandemic on robot-assisted radical prostatectomy and urologists' treatment behaviors: A single tertiary center retrospective study.
     Int J Urol. 2024;31:899-905.
     

     >> Share

     
     July 2024
136. KOHJIMOTO Y, Uemura H, Yoshida M, Hinotsu S, et al
     Japanese clinical practice guidelines for prostate cancer 2023.
     Int J Urol. 2024 Jul 30. doi: 10.1111/iju.15545.
     

     >> Share

     
     
137. URABE F, Muramoto K, Yanagisawa T, Fukuokaya W, et al
     Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
     Int J Urol. 2024 Jul 19. doi: 10.1111/iju.15546.
     

     >> Share

     
     
138. AIZAWA R, Ishikawa H, Kato M, Shimizu S, et al
     Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.
     Int J Urol. 2024 Jul 17. doi: 10.1111/iju.15535.
     

     >> Share

     
     
139. SUN Q, Du K, Sun S, Liu Y, et al
     Local treatment benefits patients with oligometastatic prostate cancer: A systematic review and meta-analysis.
     Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15540.
     

     >> Share

     
     
140. DELLA CORTE M, Checcucci E
     Editorial Comment on "The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery".
     Int J Urol. 2024 Jul 9. doi: 10.1111/iju.15543.
     

     >> Share

     
     
141. DI BELLO F, Fraia A, Pezone G, Colla Ruvolo C, et al
     The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery.
     Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15516.
     

     >> Share

     
     June 2024
142. SAITO K, Kohada Y, Hieda K, Shikuma H, et al
     Preoperative high serum total testosterone levels predict preserved postoperative sexual function in patients after nerve-sparing robot-assisted radical prostatectomy.
     Int J Urol. 2024 Jun 7. doi: 10.1111/iju.15511.
     

     >> Share

     
     
143. TANABE K, Kobayashi S, Tamiya T, Konishi T, et al
     Risk factors for the long-term persistent genitourinary toxicity after stereotactic body radiation therapy for localized prostate cancer: A single-center, retrospective study of 306 patients.
     Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15507.
     

     >> Share

     
     
144. HASHIMOTO K, Kosaka T, Terada N, Kimura T, et al
     Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023.
     Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15499.
     

     >> Share

     
     
145. KATO M, Shiota M, Kimura T, Hanazawa R, et al
     Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
     Int J Urol. 2024;31:662-669.
     

     >> Share

     
     May 2024
146. WATANABE H, Nakane K, Takahara K, Naiki T, et al
     Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
     Int J Urol. 2024 May 19. doi: 10.1111/iju.15498.
     

     >> Share

     
     
147. URABE F
     The relevance of circRNAs in serum of patients undergoing prostate biopsy.
     Int J Urol. 2024;31:581.
     

     >> Share

     
     
148. SAMIRAE L, Krausewitz P, Alajati A, Kristiansen G, et al
     The relevance of circRNAs in serum of patients undergoing prostate biopsy.
     Int J Urol. 2024;31:578-580.
     

     >> Share

     
     
149. CHIARELLI G, Davis M, Stephens A, Cirulli GO, et al
     Comparison of patient background between a real-world North American cohort and the Goteborg-2 trial.
     Int J Urol. 2024;31:562-567.
     

     >> Share

     
     
150. ANDO S, Sugihara T, Hinotsu S, Kishino H, et al
     Early recovery of urinary continence after robot-assisted radical prostatectomy is associated with membranous urethra and neurovascular bundle preservation.
     Int J Urol. 2024;31:492-499.
     

     >> Share

     
     April 2024
151. YAMAMOTO Y, Nonomura N
     Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
     Int J Urol. 2024 Apr 4. doi: 10.1111/iju.15458.
     

     >> Share

     
     
152. BLAS L, Shiota M, Tanegashima T, Tsukahara S, et al
     Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
     Int J Urol. 2024;31:404-408.
     

     >> Share

     
     March 2024
153. URABE F, Sumiyoshi T, Tashiro K, Goto T, et al
     Prostate cancer and liquid biopsies: Clinical applications and challenges.
     Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15441.
     

     >> Share

     
     
154. GOTO Y
     Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications and challenges.
     Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15456.
     

     >> Share

     
     
155. KOBAYASHI M, Matsuoka Y, Uehara S, Tanaka H, et al
     Utility of positive core number on MRI-ultrasound fusion targeted biopsy in combination with PI-RADS scores for predicting unexpected extracapsular extension of clinically localized prostate cancer.
     Int J Urol. 2024 Mar 12. doi: 10.1111/iju.15451.
     

     >> Share

     
     
156. GOTO Y
     Editorial Comment on Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
     Int J Urol. 2024 Mar 8. doi: 10.1111/iju.15444.
     

     >> Share

     
     
157. KAWASE M, Kato D, Tobisawa Y, Iinuma K, et al
     Efficacy and safety of combination neoadjuvant chemo-hormonal therapy and robot-assisted radical prostatectomy for oligometastatic prostate cancer.
     Int J Urol. 2024 Mar 7. doi: 10.1111/iju.15448.
     

     >> Share

     
     
158. BLAS L, Shiota M, Tanegashima T, Kobayashi S, et al
     Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
     Int J Urol. 2024 Mar 5. doi: 10.1111/iju.15449.
     

     >> Share

     
     February 2024
159. PARK SJ, Park YJ, Park SM
     Response to comment: Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
     Int J Urol. 2024 Feb 15. doi: 10.1111/iju.15431.
     

     >> Share

     
     
160. OBINATA D, Takayama K, Inoue S, Takahashi S, et al
     Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
     Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15424.
     

     >> Share

     
     
161. ASAI S, Kobayashi M, Fukuda S, Kimura K, et al
     Significance of atypical nodules upgraded to category 3 in Prostate Imaging Reporting and Data System version 2.1 for prostate cancer diagnosis.
     Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15421.
     

     >> Share

     
     
162. HIYAMA Y
     Editorial Comment: Proctoscopy following transrectal prostate biopsy can control rectal bleeding after prostate biopsy.
     Int J Urol. 2024;31:143.
     

     >> Share

     
     January 2024
163. SHOJI S
     Editorial Comment to Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
     Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15406.
     

     >> Share

     
     
164. LIN YH, Chen YT, Tsai HY
     Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
     Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15401.
     

     >> Share

     
     
165. MORI K
     Editorial Comment from Dr Mori to Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
     Int J Urol. 2024 Jan 24. doi: 10.1111/iju.15402.
     

     >> Share

     
     
166. HATANO K
     Editorial Comment on "Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea".
     Int J Urol. 2024 Jan 12. doi: 10.1111/iju.15393.
     

     >> Share

     
     
167. UKIMURA O
     Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
     Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
     

     >> Share

     
     
168. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
     Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
     

     >> Share

     
     
169. OKIHARA K, Ueda T, Fujihara A, Shiraishi T, et al
     Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15389.
     

     >> Share

     
     
170. OKANO K, Miyai K, Mikoshi A, Edo H, et al
     Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15385.
     

     >> Share

     
     
171. DE VELASCO MA, Kura Y, Fujita K, Uemura H, et al
     Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
     Int J Urol. 2024 Jan 2. doi: 10.1111/iju.15378.
     

     >> Share

     
     
172. NAITO Y, Kato M, Nagayama J, Sano Y, et al
     Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
     Int J Urol. 2024;31:7-16.
     

     >> Share

     
     December 2023
173. YOKOMIZO A, Shiota M, Morokuma F, Eto M, et al
     GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
     Int J Urol. 2023 Dec 26. doi: 10.1111/iju.15371.
     

     >> Share

     
     
174. PARK SJ, Hong J, Park YJ, Jeong S, et al
     Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
     Int J Urol. 2023 Dec 21. doi: 10.1111/iju.15364.
     

     >> Share

     
     
175. NAKAZONO M, Urabe F, Iwatani K, Imai Y, et al
     Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
     Int J Urol. 2023;30:1147-1154.
     

     >> Share

     
     November 2023
176. YUASA T
     Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
     Int J Urol. 2023;30:1034-1035.
     

     >> Share

     
     
177. SHIRAISHI K
     Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire.
     Int J Urol. 2023;30:959-967.
     

     >> Share

     
     
178. BLAS L, Shiota M, Matsumoto T, Hori Y, et al
     Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
     Int J Urol. 2023;30:1029-1034.
     

     >> Share

     
     
179. KOHADA Y, Hieda K, Miyamoto S, Tasaka R, et al
     Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy.
     Int J Urol. 2023;30:1020-1027.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share